Stephen Hoge, an insider at Moderna, Inc. (MRNA), reported a change in his beneficial ownership of the company’s common stock in a Form 4 filed July 16, 2026, covering transactions dated July 15, 2026. The filing indicates that Dr. Hoge exercised a fully vested and exercisable stock option for 37,226 shares of Moderna common stock at an exercise price of $19.15 per share. The option exercise was reported with transaction code “M,” which generally denotes the exercise or conversion of a derivative security into common stock. On the same date, Hoge reported the sale of 16,110 shares of common stock at $67.60 per share. The sale was reported with transaction code “S” and was made pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans allow insiders to schedule trades in advance under predetermined conditions, reducing concerns that transactions are based on material nonpublic information. After the reported transactions, the filing lists Hoge as directly owning 1,537,184 shares of Moderna common stock. It also reports 53,336 shares held indirectly by a trust for the benefit of Dr. Hoge’s spouse and children, with his spouse serving as trustee. Hoge disclaimed Section 16 beneficial ownership of the trust-held shares except to the extent of any pecuniary interest he may have. The filing was signed on July 16, 2026, by James Dillon as attorney-in-fact.